These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

634 related items for PubMed ID: 17080911

  • 1. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time.
    Becker-Merok A, Nikolaisen C, Nossent HC.
    Lupus; 2006; 15(9):570-6. PubMed ID: 17080911
    [Abstract] [Full Text] [Related]

  • 2. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
    Vallerskog T, Heimbürger M, Gunnarsson I, Zhou W, Wahren-Herlenius M, Trollmo C, Malmström V.
    Arthritis Res Ther; 2006; 8(6):R167. PubMed ID: 17092341
    [Abstract] [Full Text] [Related]

  • 3. The significance of rheumatoid factor and anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus.
    Popescu C, Zofotă S, Bojincă V, Ionescu R.
    Rom J Intern Med; 2013; 51(3-4):179-87. PubMed ID: 24620631
    [Abstract] [Full Text] [Related]

  • 4. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
    Salazar-Camarena DC, Ortíz-Lazareno P, Marín-Rosales M, Cruz A, Muñoz-Valle F, Tapia-Llanos R, Orozco-Barocio G, Machado-Contreras R, Palafox-Sánchez CA.
    Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
    [Abstract] [Full Text] [Related]

  • 5. Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus.
    Vincent FB, Northcott M, Hoi A, Mackay F, Morand EF.
    Lupus; 2013 Aug; 22(9):873-84. PubMed ID: 23846230
    [Abstract] [Full Text] [Related]

  • 6. APRIL levels strongly correlate with IL-17 in systemic lupus erythematosus.
    Eilertsen GØ, Nossent JC.
    Lupus; 2014 Nov; 23(13):1383-91. PubMed ID: 25057039
    [Abstract] [Full Text] [Related]

  • 7. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
    Toubi E, Kessel A, Rosner I, Rozenbaum M, Paran D, Shoenfeld Y.
    Scand J Immunol; 2006 Apr; 63(4):299-303. PubMed ID: 16623930
    [Abstract] [Full Text] [Related]

  • 8. Associations of B cell-activating factor (BAFF) and anti-BAFF autoantibodies with disease activity in multi-ethnic Asian systemic lupus erythematosus patients in Singapore.
    Howe HS, Thong BYH, Kong KO, Chng HH, Lian TY, Chia FL, Tay KSS, Lau TC, Law WG, Koh ET, Leung BP.
    Clin Exp Immunol; 2017 Sep; 189(3):298-303. PubMed ID: 28388832
    [Abstract] [Full Text] [Related]

  • 9. Presence of antibodies against cyclic citrullinated peptides in patients with 'rhupus': a cross-sectional study.
    Amezcua-Guerra LM, Springall R, Marquez-Velasco R, Gómez-García L, Vargas A, Bojalil R.
    Arthritis Res Ther; 2006 Sep; 8(5):R144. PubMed ID: 16934155
    [Abstract] [Full Text] [Related]

  • 10. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
    Morimoto S, Nakano S, Watanabe T, Tamayama Y, Mitsuo A, Nakiri Y, Suzuki J, Nozawa K, Amano H, Tokano Y, Kobata T, Takasaki Y.
    Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
    [Abstract] [Full Text] [Related]

  • 11. BAFF overexpression is associated with autoantibody production in autoimmune diseases.
    Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, Youinou P.
    Ann N Y Acad Sci; 2005 Jun; 1050():34-9. PubMed ID: 16014518
    [Abstract] [Full Text] [Related]

  • 12. Preliminary clinical measurement of the expression of B-cell activating factor in Chinese systemic lupus erythematosus patients.
    Lin Z, Dan-Rong Y, Xiao-Qing T, Hao W, Hong-Lian G, Xian-Tao K, Ren-Qian Z, Jiyu L.
    J Clin Lab Anal; 2007 Jun; 21(3):183-7. PubMed ID: 17506477
    [Abstract] [Full Text] [Related]

  • 13. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus.
    Carter LM, Isenberg DA, Ehrenstein MR.
    Arthritis Rheum; 2013 Oct; 65(10):2672-9. PubMed ID: 23839909
    [Abstract] [Full Text] [Related]

  • 14. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus.
    Salazar-Camarena DC, Ortiz-Lazareno PC, Cruz A, Oregon-Romero E, Machado-Contreras JR, Muñoz-Valle JF, Orozco-López M, Marín-Rosales M, Palafox-Sánchez CA.
    Lupus; 2016 May; 25(6):582-92. PubMed ID: 26424128
    [Abstract] [Full Text] [Related]

  • 15. Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis.
    Becker-Merok A, Kalaaji M, Haugbro K, Nikolaisen C, Nilsen K, Rekvig OP, Nossent JC.
    Arthritis Res Ther; 2006 May; 8(6):R162. PubMed ID: 17062137
    [Abstract] [Full Text] [Related]

  • 16. Autoantibodies to box A of high mobility group box 1 in systemic lupus erythematosus.
    Schaper F, de Leeuw K, Horst G, Maas F, Bootsma H, Heeringa P, Limburg PC, Westra J.
    Clin Exp Immunol; 2017 Jun; 188(3):412-419. PubMed ID: 28245520
    [Abstract] [Full Text] [Related]

  • 17. Decreased serum thrombospondin-1 and elevation of its autoantibody are associated with multiple exacerbated clinical manifestations in systemic lupus erythematosus.
    Meng Y, Zhang M, Zhao X, Cheng Y, Jia R, Wang Y, Sun X.
    Clin Rheumatol; 2018 Oct; 37(10):2707-2714. PubMed ID: 29998369
    [Abstract] [Full Text] [Related]

  • 18. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
    Morel J, Roubille C, Planelles L, Rocha C, Fernandez L, Lukas C, Hahne M, Combe B.
    Ann Rheum Dis; 2009 Jun; 68(6):997-1002. PubMed ID: 18676986
    [Abstract] [Full Text] [Related]

  • 19. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
    Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, Stohl W.
    Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
    [Abstract] [Full Text] [Related]

  • 20. Autoantibodies to tumor necrosis factor in patients with rheumatoid arthritis and systemic lupus erythematosus.
    Rosenau BJ, Schur PH.
    J Rheumatol; 2009 Apr; 36(4):753-6. PubMed ID: 19273453
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.